10 October 2022 - Four years ago, Ontarian Rebecca Grundy got a nightmare diagnosis that sent her into a blind ...
5 October 2022 - The CADTH recommendations are a step towards public funding of this treatment option for some patients with ...
7 August 2022 - Entrectinib, a targeted drug that had shown positive results in tumours that had the same gene expression, ...
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
24 February 2022 - AbbVie announced today that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta (venetoclax) in combination ...
10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...
9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with ...
26 August 2021 - pERC recommends reimbursement of Venclexta (venetoclax) in combination with azacitidine for the treatment of newly diagnosed acute ...
28 May 2021 - BC Cancer, CPHIN and Roche Canada will co-create an evidence-generating framework to leverage real-world data and facilitate ...
21 May 2021 - Maria Stevens was diagnosed with cervical cancer two years ago. Now, with a new treatment on ...
4 May 2021 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, today ...
4 May 2021 - Zejula (niraparib) has received conditional positive recommendations for reimbursement from the Canadian Agency of Drugs and Technology ...
29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received ...
9 January 2021 - The pERC has conditionally recommended the reimbursement of nivolumab when used in combination with ipilimumab and ...
9 January 2021 - pERC has conditionally recommended the reimbursement of entrectinib for the first-line treatment of patients with ROS1 positive ...